Skip to main content
NYXH
NASDAQ Industrial Applications And Services

Nyxoah Reports Strong Q4 & FY2025 Revenue Growth, Positive Q1 2026 Guidance, and Successful U.S. Launch

Analyse IA par Wiseek
Sentiment info
Positif
Importance info
8
Prix
$5.12
Cap. de marche
$220.295M
Plus bas 52 sem.
$4.345
Plus haut 52 sem.
$11.87
Market data snapshot near publication time

summarizeResume

The preliminary financial results indicate robust performance, particularly with the substantial year-over-year revenue growth in both the fourth quarter and full year 2025. The successful U.S. commercialization, marked by surgeon training and account activation, highlights effective market penetration for its Genio system post-FDA approval. The positive revenue guidance for the first quarter of 2026 suggests continued momentum. Additionally, the disclosure of BNP Paribas Asset Management crossing the 3% ownership threshold, while attributed to an internal merger, signifies increased institutional presence. These factors collectively paint a positive picture for Nyxoah's operational trajectory and investor confidence.


check_boxEvenements cles

  • Strong Revenue Growth

    Preliminary Q4 2025 net revenue increased by approximately 348% year-over-year to €5.7 million, with full year 2025 net revenue growing 122% to €10.0 million.

  • Successful U.S. Commercialization

    The company reported a strong U.S. launch with approximately €3.5 million in U.S. net revenue for Q4 2025, 145 surgeons trained, and 57 accounts activated.

  • Positive Q1 2026 Guidance

    Nyxoah expects U.S. net revenue for the first quarter of 2026 to grow by approximately 25% over Q4 2025.

  • Solid Cash Position

    As of December 31, 2025, cash, cash equivalents, and financial assets were approximately €47.9 million.


auto_awesomeAnalyse

The preliminary financial results indicate robust performance, particularly with the substantial year-over-year revenue growth in both the fourth quarter and full year 2025. The successful U.S. commercialization, marked by surgeon training and account activation, highlights effective market penetration for its Genio system post-FDA approval. The positive revenue guidance for the first quarter of 2026 suggests continued momentum. Additionally, the disclosure of BNP Paribas Asset Management crossing the 3% ownership threshold, while attributed to an internal merger, signifies increased institutional presence. These factors collectively paint a positive picture for Nyxoah's operational trajectory and investor confidence.

Au moment de ce dépôt, NYXH s'échangeait à 5,12 $ sur NASDAQ dans le secteur Industrial Applications And Services, pour une capitalisation boursière d'environ 220,3 M $. La fourchette de cours sur 52 semaines allait de 4,35 $ à 11,87 $. Ce dépôt a été évalué avec un sentiment de marché positif et un score d'importance de 8 sur 10.

descriptionVoir le depot SEC principal

show_chartGraphique des prix

Partager cet article

Copied!

feed NYXH - Dernieres analyses

NYXH
Mar 26, 2026, 4:01 PM EDT
Filing Type: 20-F
Importance Score:
9
NYXH
Mar 19, 2026, 5:04 PM EDT
Filing Type: 6-K
Importance Score:
8
NYXH
Mar 19, 2026, 4:10 PM EDT
Source: GlobeNewswire
Importance Score:
8
NYXH
Jan 30, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
8
NYXH
Jan 14, 2026, 4:05 PM EST
Filing Type: 6-K
Importance Score:
8